04:22 , Apr 7, 2017 |  BC Week In Review  |  Company News

Avillion, Merck KGaA deal

The companies partnered to develop Merck’s M1095 (ALX-0761) to treat plaque psoriasis. Avillion will be responsible for developing the candidate through Phase III testing and will also finance development through to a regulatory submission. Phase...
02:11 , Feb 23, 2017 |  BC Week In Review  |  Clinical News

M1095: Ph Ib data

A double-blind, German Phase Ib trial in 41 patients with moderate to severe psoriasis showed that 30, 60, 120 and 240 mg doses of subcutaneous M1095 on days 1, 15 and 29 led to PASI...
02:37 , Feb 28, 2015 |  BC Extra  |  Company News

Ablynx: Merck Serono may unwind deal

Ablynx N.V. (Euronext:ABLX) said during its 4Q14 earnings call that partner Merck Serono S.A. is likely to terminate a 2013 deal to develop Nanobodies against cancer, immunology and neurology targets. Ablynx did not respond to...
07:00 , Jul 1, 2013 |  BC Week In Review  |  Clinical News

ALX-0761: Phase I started

Ablynx said Merck's Merck Serono S.A. unit began a double-blind, placebo-controlled Phase I trial to evaluate single ascending-doses of subcutaneous ALX-0761 in healthy volunteers. The start triggers a €2.5 million ($3.3 million) milestone payment to...
07:00 , Oct 1, 2012 |  BC Week In Review  |  Company News

Ablynx, Merck KGaA deal

Ablynx will receive a €1 million ($1.3 million) milestone payment from Merck under a 2008 deal in which Ablynx and Merck's Merck Serono S.A. unit partnered to co-discover and co-develop Ablynx 's Nanobodies against two...
08:00 , Dec 19, 2011 |  BC Week In Review  |  Company News

Ablynx, Merck KGaA deal

Ablynx will receive a €1 million ($1.3 million) milestone payment from Merck under a 2008 deal in which Ablynx and Merck's Merck Serono S.A. unit partnered to co-discover and co-develop Ablynx's Nanobodies against two undisclosed...